A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
Status:
Terminated
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
Pulmonary arterial hypertension (PAH) is characterized by premature death mainly because of
progressive and severe right ventricular failure. Target drugs are reported to be associated
with significant improvement of clinical outcome for PAH patients. However, previous studies
using those target drugs focused on the change of 6-minute walk distance (6MWD) and or
hemodynamic responses. As 6MWD has weak correlation with clinical outcome (time to clinical
worsening, TTCW), benefits from target drugs for PAH patients are not clear. We previously
reported the safety and efficacy of pulmonary artery denervation (PADN) for treatment of PAH
patients who were unresponsive to target drugs. Hence, we design the randomized study to
identify the effect of PADN on PAH.
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University The First Affiliated Hospital with Nanjing Medical University